SLC1A5 and acute myeloid leukemia: Recently, studies have indicated that suppressing SLC1A5 by RNA interference or pharmacological inhibition can effectively prevent cancer development and progression in human AML xenograft mouse models, which appears to be associated with glutamine uptake and mTORC1 pathway [39, 50].